Figure S1. Study design. SC, subcutaneous.

Figure S2. Pharmacokinetics of quilizumab in asthma patients. Symbols indicate observed values; lines indicate predicted values. M, monthly; Q, quarterly; SD, standard deviation.

Figure S3. Effect of quilizumab on blood eosinophils (A, B) and FeNO (C, D) from baseline to Week 36. Levels were represented as the mean ± standard error (SE; A, C) and the mean ± SE percent change from baseline (B, D). All data analysis was based on observed values. M, monthly; Q, quarterly.